NEW YORK, Aug. 22 – Galapagos Genomics is collaborating with Vertex Pharmaceuticals to identify the function of various proteins, the company announced on Wednesday.

Galapagos, a privately held company based in Mechelen, Belgium, will provide Vertex with recombinant adenoviruses via its PhenoSelect expression platform. Vertex plans to use the information to characterize protein activity within targeted biological pathways.

Financial details of the collaboration were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.